Profile

Who we are…and what we do…

Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.

Beta cell replacement is one of the most promising approaches for treatment of Insulin Dependent Diabetes Mellitus (IDDM). Currently, pancreas islet transplantation is the only approved cell replacement technology and it's the best available treatment for diabetics. However, it's impractical because of a shortage of donor tissue and rejection rate by the patient' immune system. Orgenesis believes that converting the diabetic patients own tissue to insulin producing cells will overcome the problem of donor shortage. Moreover, since the diabetic patient serves as his/her own donor, there is no risk of transplant rejection.

Orgenesis has manifested promising results in in-vitro and in-vivo studies using human liver tissues. Based on this significant discovery and these findings, Orgenesis has designed an efficient and clear work-plan to initiate clinical testing in the next few months allowing the company to launch phase I clinical trials following FDA guidelines followed by the launch of Phase II clinical trials within a year.

Orgenesis’ technology is based on IP licensed from Israel’s acclaimed Sheba Medical Center. This portfolio is based on the groundbreaking work and two decades of research by the world renowned researcher, Prof. Sarah Ferber.

Prof. Ferber is the head of the endocrine research unit at Sheba Medical Center. Prof. Ferber’s research work has been funded over the past 10 years by the JDRF, the Israel Academy of Science foundation (ISF) and D-Cure a non-profit organization that promotes and funds scientific research in Israel, aimed at finding a cure and better treatments for diabetes (together, over US$4M). Ferber graduated at the Technion (Israel Institute of Technology) where she performed her undergraduate and graduate studies under the supervision of Prof. Avram Hershko and Aaron Ciechanover, respectively. She participated in the studies which led the two scientists to receive the Nobel Prize (Chemistry) in 2004. Prof. Ferber completed her Post-Doctorate studies at Harvard University and established her own research group at the Sheba Medical Center in Israel in 1993 where she supervises about 40 undergraduate, graduate and Post-Doctoral students. Her research is financed by over 4 million dollars in competitive grants. Prof. Ferber is a member of the Israeli and European Societies for Gene and Cell therapy, and serves on the board of several peer-reviewed scientific journals. 

Two patents have been issued titled “Methods Of Inducing Regulated Pancreatic Hormone Production” and "Methods Of Inducing Regulated Pancreatic Hormone Production In Non-Pancreatic Islet Tissues" which were written by Mintz Levin patent attorney office and filed in the USA, Japan, Australia, Canada, European Patent Convention, France, Germany, Italy and United Kingdom on Prof. Ferber's research in the field of converting cells from adult organs into insulin producing tissue.

Orgenesis’ CEO, Mr. Jacob BenArie, is the former CEO of Beta-Stim Ltd., a developer of a novel implantable neurostimulator to treat type 2 diabetes. Mr. BenArie possesses extensive practical and managerial experience in the fields of medical development across a number of areas within the sector. Mr. BenArie earned an MBA degree and a B.Sc. in engineering from the Technion Institute of Technology, Israel.

The company's technology has been developed following extensive animal safety testing and the research has matured to the stage of clinical development , There are over 50 centers in the world that are highly qualified for Pancreatic Islet transplantation. It is Orgenesis’ intention to work closely with such leading centers in order to enable Autologous Insulin Producing (AIP) cell transplantation as a therapeutic approach in the treatment of diabetes at those centers. 


Back to Top